BioNTech (BNTX) Stock Price Target 2026

The average analyst price target for BioNTech is $127.16, 45.4% above the current price. Of 17 analysts, 13 rate it Buy and 4 Hold. Targets range from $94 to $171.44. The latest change came on Nov 9, 2026, when HC Wainwright & Co. lowered its price target on BioNTech from $130 to $110 and kept a Buy rating.

The Average Analyst Price Target for BioNTech is $127.16.

Price Target Range — 12 Quarters

Analyst Consensus — 17 Analysts

13Buy

4Hold

Consensus RatingBuy# Analysts17Avg. Consensus PT$127.16Upside to Avg. PT+45.4%

Rating Trend — Last 9 Months

Latest Upgrades and Downgrades for BioNTech Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Nov 9, 2026	HC Wainwright & Co.	Robert Burns	PT Cut	Buy	$130→$110
Nov 4, 2026	UBS	David Dai	PT Cut	Buy	$135→$125
Nov 4, 2026	Morgan Stanley	Terence Flynn	PT Cut	Overweight	$114→$106
Nov 4, 2026	Wells Fargo	Mohit Bansal	PT Cut	Overweight	$140→$125
Nov 4, 2026	Evercore ISI Group	Cory Kasimov	PT Cut	Outperform	$120→$110
Oct 14, 2026	Canaccord Genuity	John Newman	PT Cut	Buy	$136→$132
Oct 7, 2026	Morgan Stanley	Terence Flynn	PT Cut	Overweight	$115→$114
Sep 8, 2026	BMO Capital	Evan Seigerman	Downgrade	Outperform→Market Perform	$128→$105
Aug 31, 2026	Canaccord Genuity	John Newman	PT Cut	Buy	$142→$136
Aug 5, 2026	Citigroup	Geoff Meacham	PT Cut	Buy	$130→$125
Aug 5, 2026	Evercore ISI Group	Cory Kasimov	PT Cut	Outperform	$135→$130
Jul 8, 2026	Morgan Stanley	Terence Flynn	PT Cut	Overweight	$126→$119
May 27, 2026	UBS	David Dai	Upgrade	Neutral→Buy	$117→$135
May 22, 2026	Bernstein	Jeffrey Walch	Initiate	Market Perform	$96
May 6, 2026	Canaccord Genuity	John Newman	PT Cut	Buy	$171→$158
May 6, 2026	Wells Fargo	Mohit Bansal	PT Cut	Overweight	$150→$140
Apr 27, 2026	HC Wainwright & Co.	Robert Burns	Maintained	Buy	$130
Apr 10, 2026	Morgan Stanley	Terence Flynn	PT Raise	Overweight	$125→$126
Mar 31, 2026	HC Wainwright & Co.	Robert Burns	PT Cut	Buy	$140→$130
Mar 11, 2026	Morgan Stanley	Terence Flynn	PT Cut	Overweight	$134→$125